Last reviewed · How we verify

NCT06909578: MOCA II

Microvascular Obstruction Diagnosis Using the CoFI™ System Assessment - II

Not yet recruiting NA Last updated 10 July 2025
What this trial tests

NA trial testing CorFlow Controlled Flow Infusion System - CoFI™ in Microvascular Obstruction (MVO) in 200 participants. Not yet recruiting.

Timeline
1 September 2025
Primary endpoint
1 December 2026
1 December 2026

Quick facts

Lead sponsorCorFlow Therapeutics AG
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment200
Start date1 September 2025
Primary completion1 December 2026
Estimated completion1 December 2026

Drugs / interventions tested

Conditions studied

Sponsor

CorFlow Therapeutics AG

Who can join

18 and older, any sex, with Microvascular Obstruction (MVO) or STEMI - ST Elevation Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective, multicenter, international single-arm, pivotal clinical study designed to validate the performance of the CoFI system in detecting MVO in STEMI subjects, as confirmed by CMRI. The study will be conducted in accordance with the Declaration of Helsinki, EN ISO 14155:2020, local and national regulations. Each study site will receive support from a sponsor-certified proctor during the learning curve to ensure consistent and accurate application of the CoFI system.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of CorFlow Controlled Flow Infusion System - CoFI™

Trials testing the same drug.

Other CorFlow Therapeutics AG trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06909578.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing